Articles On Immutep (ASX:IMM)
| Title | Source | Codes | Date |
|---|---|---|---|
|
ASX Shaken as Gold Miners Reel Amid Global Tensions
Highlights ASX weakened as global risk concerns rose. Gold miners faced broad pressure. Defensive sectors showed relative resilience. The Australian share market ended weaker as global tensions, firmer oil prices, and... |
Kalkine Media | IMM | 1 day ago |
|
Health Check: Cancer assay developer BCAL finds quickest, breast route to the US
BCAL has partnered with the giant Sonic Healthcare to introduce its breast cancer tests to the US market Our drug is no duster, says Immutep Nexalis lands new funding after lender fallout Breast cancer assay developer BCAL Diagnostics (... |
Stockhead | IMM | 1 day ago |
|
Dr Boreham’s Crucible: A reinvented Racura on the path to commercialisation
Racura executive chair Dr Peter Smith acknowledges investor sentiment towards the local biotech sector is not great, given a string of recent trial setbacks. Not to put too fine a point on it, many of Racura Oncology (ASX:RAC) ASX peers hav... |
Stockhead | IMM | 3 days ago |
|
Short Sellers Circle ASX 200 Stocks as Market Sentiment Shifts
Highlights Short interest stays active across ASX mining and tech shares Rare earth and uranium companies remain under close watch Several ASX consumer and financial stocks attract renewed attention Short selling activ... |
Kalkine Media | IMM | 1 week ago |
|
ASX 200 Slips as Miners Weigh on Market Mood
Highlights Mining shares weakened as copper and gold prices eased. Technology and financial stocks helped cushion the market. Global bond yields and China concerns shaped sentiment. Australian shares ended softer as mi... |
Kalkine Media | IMM | 2 weeks ago |
|
Health Check: Resmed goes out on a limb with its ‘restless leg’ purchase
Sleep apnoea giant Resmed splurges $US360 million ($500m) to buy a company tackling restless leg syndrome April was the cruellest month for ASX biotechs Arovella coup claims more scalps Having conquered sleep apnoea (snoring), ResMed (... |
Stockhead | IMM | 3 weeks ago |
|
ASX biotechs face final hurdle as Phase III catalysts loom
Phase III trials are a major catalyst for healthcare companies, mark final proving ground before potential regulatory approval and commercialisation Success can make or break a company with several ASX healthcare names now in the high-stak... |
Stockhead | IMM | 4 weeks ago |
|
Biocurious: Stay tuned as drug developers get to the pointy end of their efforts
A gaggle of drug developers is due to disclose company-making clinical study results this year While late-stage clinical trial victory does not confer commercial success, the results tend to be ‘do or die’ In the main, share valuations don... |
Stockhead | IMM | 1 month ago |
|
The Biotech ‘Industrialisation’
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Australian biotechs are successfully turning promising science into a scalable, repe... |
FNArena | IMM | 1 month ago |
|
ASX Runners of the Week: Bison, Genetic Signatures, Narryer & Immutep
The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime Nevada gold-silver projects amid ongoing fuel security chaos. |
The West | IMM | 1 month ago |
|
Closing Bell: ASX falls flat as financials index flips red
ASX crawls just 0.09% higher Financials gives up gains, unwinding market momentum Energy, utilities drag as US-Iran ceasefire continues Market struggles to hold momentum It was relatively quiet on the Middle Eastern front, with no dramati... |
Stockhead | IMM | 1 month ago |
|
ASX 200 Midday Movers: Tech Rises, Energy Slips
Highlights Market edges higher on easing oil prices Tech and gold stocks lead sector gains Energy and banks weigh on sentiment ASX 200 edged higher at midday, driven by gains in technology and gold stocks, while energy and financi... |
Kalkine Media | IMM | 1 month ago |
|
Why this ASX biotech stock just rocketed 89% today
Immutep Ltd (ASX: IMM) shares are having a rare breakout session on Wednesday. After spending most of the year under relentless selling pressure, the biotech stock has suddenly sprung back to life. At the time of writing, Immutep shar... |
Motley Fool | IMM | 1 month ago |
|
Top 10 at 11: ASX creeps higher as US-Iran ceasefire holds
Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks... |
Stockhead | IMM | 1 month ago |
|
Dr Boreham’s Crucible: Positive Alzheimer’s portents for Actinogen Medical
Following the clinical trial setbacks from drug developers Opthea, Immutep, Percheron and Argenica Therapeutics, the local sector could really do with a win. Actinogen Medical (ASX:ACW) could be the one to pull the sector out of its funk –... |
Stockhead | IMM | 1 month ago |
|
Health Check: The biotech winners and losers from a messy March of mayhem
The Ides of March weighed down the sector, but green shoots of recovery may make April fools of the naysayers Telix Pharmaceuticals shares led the top end recovery with a 40% gain It’s April – and drug developers with names starting with ‘... |
Stockhead | IMM | 1 month ago |
|
This ASX 200 stock just hit a multi-year low. Here's what's behind the slide
The CAR Group Ltd (ASX: CAR) share price is once again in the red on Friday. At the time of writing, shares are down 1.92% to $22.51, after falling as low as $22.19 earlier in the session. That marks a multi-year low, with the stock now... |
Motley Fool | IMM | 2 months ago |
|
Guess which ASX mining stock is crashing 24% today
Syrah Resources Ltd (ASX: SYR) shares are crashing deep into the red on Friday. In morning trade, the ASX mining stock is down 24% to a multi-year low of 11 cents. Why is this ASX mining stock crashing? Investors have been selling the graph... |
Motley Fool | IMM | 2 months ago |
|
Health Check: Amplia shares almost double on pancreatic cancer trial results
Pancreatic cancer is normally a death sentence, but five patients in Amplia’s studies have emerged tumour free It’s a case of ‘good golly Molly’ as medical pot platform joins the psychedelics push Nexsen wins positive FDA feedback on its p... |
Stockhead | IMM | 2 months ago |
|
ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia
The Bulls N’ Bears ASX Runner of the Week is… Immutep. In a slightly perverse twist, the oncology mid-cap bounced hard from last week’s 90 per cent drop, gaining 53 per cent after a brutal sell-off. |
The West | IMM | 2 months ago |
|
HotList stocks: Northern Star, Immutep, Lodestar, and other trending companies in Week 12
Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX companies of every shape and size go through the ups and downs that is the Australian trading rollercoaster. Fortunes made, and equity lost each time the bourse op... |
themarketonline.com.au | IMM | 2 months ago |
|
The Overnight Report: No Recovery Rally
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Oil first rallied, then retreated. Equities played the opposite card, recovering tow... |
FNArena | IMM | 2 months ago |
|
Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that
In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded alike) are chasing down new targets for 2026. Listen to the HotCopper podcast for in-depth discussion... |
themarketonline.com.au | IMM | 2 months ago |
|
Thursday’s HotCopper trends: Racura, EVR, Immutep, and other daily topics | March 19
Racura is well out in front on the Australian bourse topic-wise today – and has had the single biggest jump price-wise – even under what has been a brutal Thursday selling day, though it’s followed closely by another healthcare company (a w... |
themarketonline.com.au | IMM | 2 months ago |
|
Down 87% since Friday, why is this ASX 300 healthcare stock sliding again today?
S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th... |
Motley Fool | IMM | 2 months ago |
|
Down 87% since Thursday, why is this ASX 300 healthcare stock sliding again today?
S&P/ASX 300 Index (ASX: XKO) healthcare stock Immutep Ltd (ASX: IMM) has been on a decidedly wild ride these past four trading days. After entering a trading halt on Monday, 9 March, Immutep shares resumed trading last Friday. And by th... |
Motley Fool | IMM | 2 months ago |
|
Market Open: Escalating war in Iran sends traders for hills; oil boils up to $110/Bbl | March 19
ASX today − Yesterday morning, I suggested Australian traders were waiting for a sign before deciding which way to go. Well, just a day later, oil’s boiling up to $110/barrel and the ASX is heading for a -1.71% collapse. Listen to the Ho... |
themarketonline.com.au | IMM | 2 months ago |
|
The Overnight Report: Cautiously Optimistic
This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Equities traded modestly higher overnight as cautiously optimistic investors await f... |
FNArena | IMM | 2 months ago |
|
How does Bell Potter rate these ASX healthcare stocks?
Bell Potter has been running the rule over a number of small-cap ASX healthcare stocks this week. Let's see what the broker is saying about these speculative stocks. Immutep Ltd (ASX: IMM) Immutep is a clinical-stage biopharmaceutical comp... |
Motley Fool | IMM | 2 months ago |
|
Closing Bell: ASX rallies back into the green on split St Patrick’s Day RBA hike decision
ASX rises 0.36% after falling into negative territory just before the RBA decision RBA votes to rase cash rate to 4.1% in 5v4 split decision Real estate and gold stocks lead gains RBA hikes rates in split decision The Reserve Bank did exa... |
Stockhead | IMM | 2 months ago |
|
Why this beaten down $9 billion ASX 200 share is now a buy
S&P/ASX 200 Index (ASX: XJO) share CAR Group Ltd (ASX: CAR) is slipping today. Shares in the auto listings company closed yesterday trading for $24.21. In morning trade on Tuesday, shares are swapping hands for $24.04 apiece, down 0.4%... |
Motley Fool | IMM | 2 months ago |
|
Northern Star Resources shares crash 22% in 2 days – These brokers say buy the dip
Northern Star Resources Ltd (ASX: NST) shares have endured an awful past week of trading. Last Friday, the ASX 200 gold stock fell more than 18%. This was followed up by a 5.3% drop on Monday. Holders of Northern Star shares wou... |
Motley Fool | IMM | 2 months ago |
|
Closing Bell: One battle after another for the ASX as headwinds take centre stage
ASX casts defensive sectors in leading roles Oil keeps the spotlight while gold loses some shine CBA and ANZ deliver supporting performances on rate-hike expectations The plot thickens for global markets While the Oscars played out in H... |
Stockhead | IMM | 2 months ago |
|
Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares
Looking for ASX shares to buy after recent market weakness? Well, if you are, let's see what analysts are saying about the popular shares in this article, courtesy of The Bull. Are they buys, holds, or sells? Let's find out: Brainchip Hold... |
Motley Fool | IMM | 2 months ago |
|
ASX 200 Rotation Alert: Defensive Sectors Rise as Gold Weakens
Highlights Defensive sectors attract attention as commodity pressure reshapes market sentiment Energy and consumer staples display resilience in early trading activity Several small-cap companies record notable movement acro... |
Kalkine Media | IMM | 2 months ago |
|
ASX 200 Turbulence: Energy Shock and Gold Slump Stir Markets
Highlights Energy shocks and global tensions are reshaping sentiment across Australian equities Gold and materials counters face renewed pressure amid commodity volatility Select companies gain attention as the market search... |
Kalkine Media | IMM | 2 months ago |
|
Top 10 at 11: ASX rotates into defensive sectors as gold slides
Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks... |
Stockhead | IMM | 2 months ago |
|
Guess which ASX All Ords stock is jumping higher today on big Tesla news
The All Ordinaries Index (ASX: XAO) is down 0.3% today, but that's not holding back this ASX All Ords stock. The outperforming stock in question is minerals and technology company Syrah Resources Ltd (ASX: SYR). Syrah Resources shares close... |
Motley Fool | IMM | 2 months ago |
|
What Bell Potter is saying about this fallen ASX 200 gold giant
Northern Star Resources Ltd (ASX: NST) shares have been struggling in recent months. Due to production issues, the ASX 200 gold giant is down 32% from its 52-week high to $21.75. While this is disappointing for shareholders, Bell Potter thi... |
Motley Fool | IMM | 2 months ago |
|
Northern Star Resources shares just crashed – time to buy the dip?
Northern Star Resources Ltd (ASX: NST) shares are in focus this week after the company experienced a historic crash on Friday. The share price tumbled more than 18% in a single day. It has now fallen more than 30% since the start of... |
Motley Fool | IMM | 2 months ago |
|
5 things to watch on the ASX 200 on Monday
On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week with a small decline. The benchmark index fell 0.15% to 8,617.1 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 e... |
Motley Fool | IMM | 2 months ago |
|
ASX Movers Spotlight: Market Leaders and Laggards
Highlights Market activity across the ASX revealed strong divergence among sectors. Defence technology, healthcare, and infrastructure companies led the advancing side. Mining, biotech, and investment firms featured among th... |
Kalkine Media | IMM | 2 months ago |
|
Market Jitters Deepen as ASX Slides Amid Global Tensions
Highlights Rising geopolitical tensions weigh on Australian equities Mining stocks face pressure while energy and defence firms gain attention Banking sector steadies market sentiment amid rate expectations Heightened... |
Kalkine Media | IMM | 2 months ago |
|
Oil Shock Rattles ASX 200 as Mining Giants Weigh on Market
Highlights Oil surge unsettles Australian sharemarket sentiment Mining giants face pressure from rising energy costs Banking stocks display steadier momentum Global energy developments have triggered fresh volatility a... |
Kalkine Media | IMM | 2 months ago |
|
Closing Bell: ASX wobbles to weak finish as energy chaos continues
ASX slips 0.14% on Friday, but ends up 0.17% over the past five days Oil prices remain high, with Brent crude hovering around US$100/barrel Energy stocks rise alongside mining and banking majors ASX stumbles to week’s end The S&P/AS... |
Stockhead | IMM | 2 months ago |
|
Phase III Shock Sends Immutep Shares Into Steep Slide
Highlights Clinical study halt shakes confidence in biotech pipeline. Lung cancer program setback triggers sharp market reaction. Focus shifts toward remaining research programs. A halted late-stage lung cancer trial h... |
Kalkine Media | IMM | 2 months ago |
|
Scott Power: ASX healthcare sector reels after another tough week
ASX health sector falls about 2.5% for the past five days while broader market is just scraping by as the Middle East conflict takes a toll Immutep plunges 90% on Friday after abandoning its Phase III trial of lung cancer treatment Pro Me... |
Stockhead | IMM | 2 months ago |
|
HotCopper Highlights Week 11: Immutep scalped; Syrah Trump’s latest victim; Japan’s Lynas handout & more
Good Afternoon, I’m Jon Davidson, it’s a Friday and you know what that means – it’s time for HotCopper Highlights, the segment where we wrap up the stocks and company announcements you were watching and viewing the most this week on Austral... |
themarketonline.com.au | IMM | 2 months ago |
|
The ides of March come for Immutep as lung cancer trial cancellation triggers plummet
Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after it’s effectively ditched its lead candidate for the treatment of lung cancer, a move that spells doom for any biotech – the speculative trader’s speculative investme... |
themarketonline.com.au | IMM | 2 months ago |
|
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
|
SmallCaps | IMM | 2 months ago |